Kim E S, Stolar C J
Division of Pediatric Surgery, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Am J Perinatol. 2000;17(7):345-56. doi: 10.1055/s-2000-13449.
Since the first use in neonates in 1974, extracorporeal membrane oxygenation (ECMO) has been a life-saving technology for newborns with respiratory and cardiac failure. ECMO has been used to treat a variety of cardio-respiratory problems, including meconium aspiration syndrome (MAS), persistent pulmonary hypertension of the neonate (PPHN), congenital diaphragmatic hernia (CDH), sepsis, and cardiac anomalies. For this group of high-mortality neonates, ECMO has produced a survival of 76% in all newborns treated. This review article will examine the current selection criteria for ECMO, the clinical management of neonates on ECMO and discuss the long-term outcome of neonates treated with ECMO.
自1974年首次用于新生儿以来,体外膜肺氧合(ECMO)一直是治疗呼吸和心力衰竭新生儿的一项挽救生命的技术。ECMO已被用于治疗多种心肺问题,包括胎粪吸入综合征(MAS)、新生儿持续性肺动脉高压(PPHN)、先天性膈疝(CDH)、败血症和心脏畸形。对于这组高死亡率的新生儿,在所有接受治疗的新生儿中,ECMO的存活率为76%。这篇综述文章将探讨ECMO目前的选择标准、接受ECMO治疗的新生儿的临床管理,并讨论接受ECMO治疗的新生儿的长期预后。